Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 29, 2009

Domainex to Conduct Optimization for U.K. Asthma Drug Collaboration

  • Domainex will receive more than £1.5 million ($2.5 million) in fees over two years to perform lead optimization in an asthma program being undertaken by St George’s University of London. The focus is on developing a new treatment based on the inhibition of Der p1, an enzyme involved in triggering asthma attacks.

    The research will be spearheaded by St George’s University of London and the University of Manchester, which have received a £4 million ($6.6 million) grant from the Wellcome Trust’s Seeding Drug Discovery Initiative.

    Collaborating scientists at St George’s, the University of Manchester, and Domainex have already discovered drug-like compounds that inhibit Der p1. Domainex will now use its virtual screening technology, LeadBuilder, to select suitable leads, and provide St George’s with medicinal chemistry support to develop a clinical candidate.


    Related News
    Aradigm and CyDex Combine Expertise to Tackle Asthma and COPD (Sep. 6, 2007)
    Novartis Inks Pact with Adenosine Therapeutics to Develop Drugs for Diabetes and Asthma (June 18, 2007)
    Idera Extends Asthma and Allergy Collaboration with Novartis (Mar. 6, 2007)
    JHU Selects Illumina Technology to Study Asthma in African-America Population (Nov. 15, 2006)

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »